Bone marrow WT1 levels in patients with myeloid neoplasms treated with 5-azacytidine: Identification of responding patients.

Marta SantaliestraAna GarridoMaite CarricondoElena BussagliaMarta PratcoronaMaria L BlancoIgnasi GichMontserrat HoyosAlbert EsquirolIrene García-CadenasSalut BrunetRodrigo MartinoJorge SierraJosep F Nomdedéu

Published in: European journal of haematology (2019)

Further studies are needed to assess whether BM WT1 levels could be useful to predict the survival of patients with myeloid neoplasms treated with 5-azacytidine.

Keyphrases

bone marrow
newly diagnosed
end stage renal disease
dendritic cells
ejection fraction
acute myeloid leukemia
chronic kidney disease
prognostic factors
peritoneal dialysis
patient reported outcomes
case control